[Direct oral anticoagulant associated bleeding]

Area of Science:

• Pharmacology and Toxicology
• Cardiology
• Hematology

Background:

• Direct oral anticoagulants (DOACs) are widely used for stroke prevention in atrial fibrillation and venous thromboembolism treatment.
• Hemorrhagic complications are a significant concern with DOAC therapy.
• Effective management strategies for DOAC-induced bleeding are crucial.

Purpose of the Study:

• To provide an updated overview of managing bleeding complications associated with direct oral anticoagulants.
• To integrate the role of newly available and developing antidotes in DOAC reversal.
• To emphasize the importance of measuring DOAC plasma concentrations for guiding treatment decisions.

Main Methods:

• Review of current literature on DOAC-induced bleeding management.
• Analysis of available and investigational reversal agents, including specific antidotes and supportive measures.
• Discussion on the utility of pharmacokinetic monitoring (plasma concentration measurement).

Main Results:

• Idarucizumab is an approved antidote for dabigatran.
• Andexanet alfa (for anti-Xa agents) and aripazine (for all DOACs) are under development.
• Prothrombin concentrates have uncertain efficacy for DOAC reversal.
• Hemodialysis and oral charcoal are options for specific scenarios.
• DOAC plasma concentration measurement is essential for effective reversal.

Conclusions:

• Management of DOAC-induced bleeding is evolving with the advent of specific antidotes.
• The availability of idarucizumab and the development of other antidotes offer improved therapeutic options.
• Accurate DOAC plasma concentration monitoring is critical for guiding appropriate reversal strategies and improving patient outcomes.